Research programme: antibody based therapeutics - Twist Bioscience
Latest Information Update: 16 Jan 2023
At a glance
- Originator Twist Bioscience
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Checkpoint kinase inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer